Alcresta (Newton, Mass.), a developer of enzyme-based nutritional products for infants, adults and patients battling acute or chronic conditions, has raised a $10 million Series A venture capital financing. Led by Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures, the Alcresta investment follows the recent launch and $15 million Series A financing of Allena Pharmaceuticals by the same investors.
The two wholly independent companies will maintain separate product pipelines while sharing resources and leveraging the operational experience and non-systemic protein delivery expertise of the combined management team, a press release stated. Proceeds from the Alcresta financing will support discovery and development of enzyme-based nutritional products and medical devices.
Disclaimer: NCN does not warrant the accuracy, reliability, or timeliness of any NCN news item. Before relying on any NCN News item the information should be independently verified.
For more finance and investment information, visit Nutrition Capital Network news.